There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Acasti Pharma (ACST – Research Report), Omnicell (OMCL – Research Report) and MoonLake Immunotherapeutics (MLTX – Research Report) with bullish sentiments.
Acasti Pharma (ACST)
In a report released today, Oren Livnat from H.C. Wainwright reiterated a Buy rating on Acasti Pharma, with a price target of $12.00. The company’s shares closed last Monday at $2.68.
According to TipRanks.com, Livnat is a 1-star analyst with an average return of
Acasti Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $12.00.
See today’s best-performing stocks on TipRanks >>
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ACST:
- Acasti Pharma files to sell 6.59M common shares for holders
- Acasti Pharma to host KOL event on GTX-104
- Acasti Pharma to Host KOL Event on GTX-104: A Potential New Treatment Standard for Rare and Life-Threatening aneurysmal Subarachnoid Hemorrhage (aSAH)
- Biotech Alert: Searches spiking for these stocks today
- Acasti Pharma announces $7.5M private placement equity financing
